XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Mar. 31, 2020
Jun. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Cash flows from operating activities:                
Net (loss) income $ (22,002,000) $ (13,445,000) $ (11,703,000) $ (865,000)   $ (55,028,000) $ 18,306,000  
Adjustments to reconcile net (loss) income to net cash used in operating activities:                
Depreciation and amortization           614,000 1,297,000  
Remeasurement of acquisition-related contingent consideration           0 3,327,000  
Remeasurement of financing-related contingent consideration           0 435,000  
Amortization of debt discount and debt issuance costs 312,000   1,642,000     937,000 4,835,000  
Change in deferred taxes           (11,322,000) (4,582,000)  
Stock-based compensation expense           6,088,000 1,705,000  
Gain from the disposition of the hospital products 0   0   $ 0 0 (45,760,000)  
Gain from the release of certain liabilities 0   0     (166,000) 0  
Other adjustments           1,056,000 306,000  
Net changes in assets and liabilities                
Accounts receivable           0 8,281,000  
Inventories           0 (1,352,000)  
Prepaid expenses and other current assets           (54,000) 1,759,000  
Research and development tax credit receivable           3,079,000 2,036,000  
Accounts payable & other current liabilities           (201,000) (4,051,000)  
Accrued expenses           2,421,000 (6,625,000)  
Earn-out payments for contingent consideration in excess of acquisition-date fair value           0 (5,323,000)  
Royalty payments for contingent consideration payable in excess of original fair value           0 (866,000)  
Other assets and liabilities           (2,228,000) (3,337,000)  
Net cash used in operating activities           (54,804,000) (29,609,000)  
Cash flows from investing activities:                
Purchases of property and equipment           (26,000) (33,000)  
Proceeds from the disposition of the hospital products           16,500,000 17,250,000  
Proceeds from sales of marketable securities           83,726,000 30,075,000  
Purchases of marketable securities           (58,591,000) (124,254,000)  
Net cash provided by (used in) investing activities           41,609,000 (76,962,000)  
Cash flows from financing activities:                
Proceeds from the February 2020 private placement           0 60,570,000  
Proceeds from the May 2020 public offering           0 116,924,000  
Proceeds from stock option exercises and employee stock purchase plan           263,000 2,006,000  
Net cash provided by financing activities           263,000 179,500,000  
Effect of foreign currency exchange rate changes on cash and cash equivalents           (621,000) 406,000  
Net change in cash and cash equivalents           (13,553,000) 73,335,000  
Cash and cash equivalents at January 1,   $ 71,722,000   $ 9,774,000 $ 71,722,000 71,722,000 9,774,000 $ 9,774,000
Cash and cash equivalents at September 30, $ 58,169,000   $ 83,109,000     58,169,000 83,109,000 $ 71,722,000
Supplemental disclosures of cash flow information:                
Interest paid           6,469,000 6,469,000  
Income taxes paid (refund)           $ 68,000 $ (1,788,000)